| Trial ID: | L6052 |
| Source ID: | NCT02089438
|
| Associated Drug: |
Saxagliptin
|
| Title: |
DPP-4 Inhibition, Incretins and Islet Function
|
| Acronym: |
CODI24
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Saxagliptin|DRUG: Vildagliptin|DRUG: Sitagliptin
|
| Outcome Measures: |
Primary: Postprandial glucose, The area under the 180 min curves for plasma glucose after each meal, 180 min | Secondary: Postprandial insulin and glucagon, The area under the 180 min curves for plasma insulin and glucagon after each meal, 180 min|Postprandial glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), The area under the 180 min curves for plasma GLP-1 and GIP after each meal, 180 min
|
| Sponsor/Collaborators: |
Sponsor: Lund University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
24
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2014-05
|
| Completion Date: |
2017-08
|
| Results First Posted: |
|
| Last Update Posted: |
2017-08-23
|
| Locations: |
Clinical Research Department, Lund, 22185, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT02089438
|
